Aude Bonehill

List of Publications by Year in Descending Order

40 papers	2,370 citations	27 h-index	41 g-index
41 ext. papers	2,557 ext. citations	5.5 avg, IF	4.18 L-index

#	Paper	IF	Citations
40	Engineering WT1-Encoding mRNA to Increase Translational Efficiency in Dendritic Cells. *Methods in Molecular Biology*, **2016**, 1428, 115-23	1.4	1
39	Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. *Cancer Immunology, Immunotherapy*, **2015**, 64, 381-8	7.4	59
38	mRNA-based dendritic cell vaccines. *Expert Review of Vaccines*, **2015**, 14, 161-76	5.2	83
37	Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene. *Molecular Medicine Reports*, **2015**, 12, 2443-50	2.9	3
36	Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. *Cancer Immunology, Immunotherapy*, **2014**, 63, 959-67	7.4	60
35	Single-step antigen loading and maturation of dendritic cells through mRNA electroporation of a tumor-associated antigen and a TriMix of costimulatory molecules. *Methods in Molecular Biology*, **2014**, 1139, 3-15	1.4	11
34	A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. *Annals of Oncology*, **2013**, 24, 2686-2693	10.3	115
33	Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. *Journal of Immunology*, **2013**, 191, 1976-83	5.3	38
32	Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). *BioMed Research International*, **2013**, 2013, 976383	3	27
31	Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. *Molecular Therapy - Nucleic Acids*, **2013**, 2, e134	10.7	30
30	Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. *Molecular Therapy*, **2012**, 20, 1063-74	11.7	71
29	Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. *Journal of Immunological Methods*, **2012**, 377, 23-36	2.5	24
28	Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells. *European Journal of Immunology*, **2012**, 42, 1417-28	6.1	6
27	Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. *Cancer Immunology, Immunotherapy*, **2012**, 61, 1033-43	7.4	58
26	Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. *Cancer Research*, **2012**, 72, 1661-71	10.1	129
25	Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy. *OncoImmunology*, **2012**, 1, 1392-1394	7.2	13
24	Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. *Journal of Immunotherapy*, **2011**, 34, 448-56	5	110

23	Restoration of tumor equilibrium after immunotherapy for advanced melanoma: three illustrative cases. *Melanoma Research*, **2011**, 21, 152-9	3.3	11
22	Engineering dendritic cells to enhance cancer immunotherapy. *Molecular Therapy*, **2011**, 19, 841-53	11.7	94
21	Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells. *Human Gene Therapy*, **2010**, 21, 479-85	4.8	9
20	Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. *Methods in Molecular Biology*, **2010**, 629, 405-52	1.4	24
19	Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. *Clinical Cancer Research*, **2009**, 15, 3366-75	12.9	130
18	Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases. *Melanoma Research*, **2009**, 19, 385-90	3.3	3
17	Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. *Vaccine*, **2008**, 26, 3735-41	4.1	26
16	Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. *Molecular Therapy*, **2008**, 16, 1170-80	11.7	145
15	Delivery of tumor-antigen-encoding mRNA into dendritic cells for vaccination. *Methods in Molecular Biology*, **2008**, 423, 155-63	1.4	11
14	CD83 expression on dendritic cells and T cells: correlation with effective immune responses. *European Journal of Immunology*, **2007**, 37, 686-95	6.1	148
13	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. *Cancer Immunology, Immunotherapy*, **2007**, 56, 1513-37	7.4	130
12	Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. *Journal of Leukocyte Biology*, **2007**, 82, 93-105	6.5	46
11	Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. *Gene Therapy*, **2006**, 13, 630-40	4	88
10	Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. *Gene Therapy*, **2006**, 13, 1027-36	4	28
9	Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. *Journal of Gene Medicine*, **2005**, 7, 686-95	3.5	47
8	Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. *Gene Therapy*, **2005**, 12, 772-82	4	81
7	Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. *Journal of Leukocyte Biology*, **2005**, 78, 898-908	6.5	22
6	Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells. *Human Gene Therapy*, **2004**, 15, 562-73	4.8	28

5	Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. *Journal of Immunology*, **2004**, 172, 6649-57	5.3	164
4	Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. *Molecular Therapy*, **2004**, 10, 768-79	11.7	68
3	Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. *Journal of Gene Medicine* , **2003**, 5, 654-67	3.5	145
2	Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. *Cancer Gene Therapy*, **2003**, 10, 696-706	5.4	46
1	Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. *Cancer Research*, **2003**, 63, 5587-94	10.1	38